The role of angiogenic factors in preeclampsia
DOI:
https://doi.org/10.15574/HW.2024.6(175).48Keywords:
preeclampsia, fetoplacental complex, pregnant women, angiogenic growth factorsAbstract
Preeclampsia is one of the leading causes of maternal and perinatal mortality, and its timely diagnosis is complicated by the multifactorial nature of the disease. The study of angiogenic factors is of key importance for early diagnosis, monitoring, and prevention of complications.
Aim - to analyze the content of angiogenesis factors (PlGF and sVEGF) in the blood serum of pregnant women and determine their impact on preeclampsia.
Materials and methods. 110 pregnant women were examined: 60 women with preeclampsia (main group) and 50 women with physiological pregnancy (control group). 86.7% of women with preeclampsia had hemodynamic disorders of the fetoplacental complex of varying severity. The content of angiogenic factors (PlGF and sVEGF) in the blood serum was assessed in the I (10-12 weeks of pregnancy), II (18-20 weeks) and III (30-34 weeks) trimester of pregnancy. Statistical analysis was performed using Student's t-test, Mann-Whitney U-test and ANOVA analysis.
Results. A decrease in PlGF in the main group was observed from the І trimester (7.89±2.2 pg/ml) and remained below the normative values in the ІІ (83.4±14.3 pg/ml) and ІІІ (62.6±9.1 pg/ml) trimesters. sVEGF in the main group was higher than in the control group in the І (1684±188.1 pg/ml vs. 1232.26±173.9 pg/ml), the ІІ (2289±254.7 pg/ml vs. 1174.35±227.5 pg/ml) and the ІІІ (2675±301.4 pg/ml vs. 1792.19±509 pg/ml) trimesters. The sVEGF/PlGF ratio in the main group was significantly higher than in the control group: 165.6 versus 11.3 in the І trimester; 144.7 versus 18.6 in the ІІ trimester and 112.8 versus 17.3 in the ІІІ trimester. A significant influence of angiogenesis factors on the development of preeclampsia was revealed: PlGF <10 pg/ml - in the І trimester, <80 pg/ml - in the ІІІ trimester; sVEGF ≥1500 pg/ml - in the І trimester, ≥2000 pg/ml - in the ІІ trimester, ≥2500 pg/ml - in the ІІІ trimester of pregnancy.
Conclusions. Decreased PlGF and increased sVEGF in the I trimester predict a high probability of preeclampsia and are markers that allow assessing the risk of complications and ensuring timely treatment.
The study was conducted in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the local ethics committee of the participating institution. Informed consent was obtained from all patients.
No conflict of interests was declared by the authors.
References
Adu-Bonsaffoh K, Ntumy MY, Obed SA, Seffah JD. (2017). Perinatal outcomes of hypertensive disorders in pregnancy at a tertiary hospital in Ghana. BMC pregnancy and childbirth. 17(1): 388. https://doi.org/10.1186/s12884-017-1575-2; PMid:29157196 PMCid:PMC5696910
Baltajian K, Bajracharya S, Salahuddin S, Berg AH, Geahchan C, Wenger JB et al. (2016). Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 215(1): 89.e1-89.e10. https://doi.org/10.1016/j.ajog.2016.01.168; PMid:26827880
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S et al. (2018). Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 72(1): 24-43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803; PMid:29899139
Chappell LC, Cluver CA, Kingdom J, Tong S. (2021). Pre-eclampsia. Lancet. 398(10297): 341-354. https://doi.org/10.1016/S0140-6736(20)32335-7; PMid:34051884
Deinichenko O, Krutʹ Y, Siusiuka V, Kyryliuk O, Boguslavska N, Shevchenko A. (2021). Peculiarities of blood flow in the uterine arteries, factors of angiogenesis, hormonal profile and their relationships in pregnant women with hypertension. Reproductive Health of Woman. (9-10): 33-38. https://doi.org/10.30841/2708-8731.9-10.2021.252586
Gladstone RA, Ahmed S, Huszti E, McLaughlin K, Snelgrove JW, Taher J et al. (2024). Midpregnancy Placental Growth Factor Screening and Early Preterm Birth. JAMA network open. 7(11): e2444454. https://doi.org/10.1001/jamanetworkopen.2024.44454; PMid:39541121 PMCid:PMC11565265
Herman LV, Kalinovska IV. (2015) Features of placental blood flow in pregnant women with noncarrying. Buk. Med. Herald. 19(1(73)): 40-44. https://doi.org/10.24061/2413-0737.XIX.1.73.2015.10
Hong J, Crawford K, Cavanagh E, da Silva Costa F, Kumar S. (2024). Prediction of preterm birth in growth-restricted and appropriate-for-gestational-age infants using maternal PlGF and the sFlt-1/PlGF ratio-A prospective study. BJOG : an international journal of obstetrics and gynaecology. 131(8): 1089-1101. https://doi.org/10.1111/1471-0528.17752; PMid:38196326
Hurrell A, Duhig K, Vandermolen B, Shennan AH. (2018). Recent advances in the diagnosis and management of pre-eclampsia. Fac Rev. 2020;9:10. https://doi.org/10.12688/f1000research.12249.1; PMid:29560262 PMCid:PMC5832913
MacDonald TM, Walker SP, Hannan NJ, Tong S, Kaitu'u-Lino TJ. (2022). Clinical tools and biomarkers to predict preeclampsia. EBioMedicine. 75: 103780. https://doi.org/10.1016/j.ebiom.2021.103780; PMid:34954654 PMCid:PMC8718967
Masoumeh Ghorbanpour S, Wen S, Kaitu'u-Lino TJ, Hannan NJ, Jin D, McClements L. (2023). Quantitative Point of Care Tests for Timely Diagnosis of Early-Onset Preeclampsia with High Sensitivity and Specificity. Angewandte Chemie (International ed. in English). 62(26): e202301193. https://doi.org/10.1002/anie.202301193; PMid:37055349
McLaughlin K, Hobson SR, Chandran AR, Agrawal S, Windrim RC, Parks WT et al. (2022). Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction. American journal of obstetrics and gynecology. 226(2S): S1145-S1156.e1. https://doi.org/10.1016/j.ajog.2021.08.027; PMid:34461078
Pavlakovic H, Becker J, Albuquerque R, Wilting J, Ambati J. (2010) Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y Acad Sci. 1207; Suppl 1: E7-E15. https://doi.org/10.1111/j.1749-6632.2010.05714.x; PMid:20961309 PMCid:PMC3062194
Stepan H, Hund M, Andraczek T. (2020). Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome. Hypertension. 75(4): 918-926. https://doi.org/10.1161/HYPERTENSIONAHA.119.13763; PMid:32063058 PMCid:PMC7098437
Teka H, Yemane A, Abraha HE, Berhe E, Tadesse H, Gebru F et al. (2023). Clinical presentation, maternal-fetal, and neonatal outcomes of early-onset versus late onset preeclampsia-eclampsia syndrome in a teaching hospital in a low-resource setting: A retrospective cohort study. PloS one. 18(2): e0281952. https://doi.org/10.1371/journal.pone.0281952; PMid:36848332 PMCid:PMC9970097
Zur RL, McLaughlin K, Aalto L, Jiang Y, Huszti E et al. (2024). Phenotypes of maternal vascular malperfusion placental pathology and adverse pregnancy outcomes: A retrospective cohort study. BJOG : an international journal of obstetrics and gynaecology. 131(11): 1515-1523. https://doi.org/10.1111/1471-0528.17837; PMid:38725333
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
